1) antitumor platinum drugs
铂类抗肿瘤药物
1.
The progress in non-classical antitumor platinum drugs are reviewed.
本文综述了非经典铂类抗肿瘤药物的发展概况 ,介绍了具有口服活性的铂 (Ⅳ )配合物 ,具有空间位阻的铂 (Ⅱ )配合物 ,反式铂 (Ⅱ、Ⅳ )配合物 ,多核铂 (Ⅱ )配合物和含有铂 硫键的铂 (Ⅱ )配合物 ,并总结了这几类新型铂配合物的抗肿瘤机理 ,克服顺铂的耐药性机理及其临床进展。
2) Platinum
铂类
1.
Clinical study of docetaxel combined with platinum for treatment of 58 cases recurrent ovarian carcinoma;
多帕菲联合铂类治疗复发转移性卵巢癌58例临床分析
2.
Objective To compare the efficacy and toxicity of NVB plus platinum protocol with CAP protocol for advanced non-small-cell lung cancer.
目的 比较去甲长春花碱 (NVB)联合铂类方案和CAP(环磷酰胺 ,阿霉素和顺铂 )方案对晚期非小细胞肺癌 (non -small -celllunfcancer ,NSCLC)的疗效与毒性。
3) Platinum
铂类药物
1.
Objective: To investigate the expression of ERCC1 and the correlation with platinum-based chemotherapy sensitivity in advanced non-small cell lung cancer (NSCLC) as well as its clinical prognostic significance.
结论:ERCC1表达不同是晚期NSCLC患者化疗方案中铂类药物敏感性差别的重要因。
4) platinum complexes
铂类制剂
1.
Efficacy and safety of pemetrexed combined with platinum complexes in the treatment of malignant pleural mesothelioma;
培美曲塞联合铂类制剂治疗恶性胸膜间皮瘤的有效性与安全性
5) platinum-sensitive
铂类敏感
1.
Objectives: (1) To determine the efficacy of chemotherapy in comparison with another chemotherapy in the treatment of patients with platinum-sensitive recurrent ovarian cance.
目的：1)确定哪些化疗对铂类敏感型复发性卵巢癌更有效。
6) platinum-based complex
铂类配合物
1.
In this paper,a new platinum-based complex,3-chloro-1,1-dicarboxycyclobutane diammine platinum(II) was synthesized and its structures was characterized by element analysis,MS,IR,and 1H-NMR.
根据目前临床使用的铂类抗癌药物的缺点和不足,作者报道了一种结构新颖的铂类配合物的合成方法,通过元素分析、质谱、红外和核磁共振氢谱等对合成物进行了结构表征,确认合成物为目标化合物。
参考词条
补充资料：抗代谢类抗肿瘤药物
抗代谢类抗肿瘤药物
antimetabolite agents
此类抗癌药对核酸代谢物与酶结合反应有相互竞争作用，影响与阻断了核酸的合成，如氟尿嘧啶、甲氨蝶呤、呋喃氟尿嘧啶、阿糖胞苷等。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。